Why Is Larry Robbins Bullish on Rapid Micro Biosystems, Inc. (RPID) Now?

We recently compiled a list of the Billionaire Larry Robbins’ Long-Term Stock Picks. In this article, we are going to take a look at where Rapid Micro Biosystems, Inc. (NASDAQ:RPID) stands against Larry Robbins’ other long-term stock picks.

Larry Robbins is an American hedge fund manager, philanthropist, and the founder, CEO, and portfolio manager of Glenview Capital, a leading New York-based investment firm. Known for his sharp analytical skills and a focus on the healthcare sector, Robbins has built a reputation as one of the most influential figures in the hedge fund industry. He was born in 1983 and grew up in a middle-class family in New Jersey. He displayed a keen interest in mathematics and analytics from an early age, which later guided his career in finance. Robbins graduated from the Wharton School of the University of Pennsylvania with a degree in economics. While at Wharton, he developed a deep understanding of market structures, investment strategies, and corporate behavior, which became the foundation of his success in the hedge fund world.

Read more about these developments by accessing 10 Best AI Data Center Stocks and 10 Buzzing AI Stocks According to Goldman Sachs.

Before founding Glenview Capital, Robbins worked as a portfolio manager at Omega Advisors, a prominent hedge fund founded by Leon Cooperman. In 2000, Larry Robbins founded Glenview Capital, which quickly rose to prominence as one of the most successful hedge funds in the world. The firm specializes in fundamental, research-driven investing and focuses on sectors such as healthcare, technology, and consumer goods. Glenview’s annualized returns have been strong, with some years delivering returns above 20%. As of the end of the third quarter of 2024, Glenview Capital manages approximately $5.7 billion in 13F securities. Robbins is particularly known for his expertise in healthcare investing, where he has consistently identified undervalued opportunities.

Read more about these developments by accessing 30 Most Important AI Stocks According to BlackRock and Beyond the Tech Giants: 35 Non-Tech AI Opportunities.

For this article, we selected stocks by combing through the 13F portfolio of Glenview Capital at the end of the third quarter of 2024. Only the companies that have been in the 13F portfolio of the fund consistently for the past three years were selected. These stocks are also popular among other hedge funds. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).

A pharmacist holding up a bottle of pharmaceutical grade product for inspection.

Rapid Micro Biosystems, Inc. (NASDAQ:RPID)

Number of Hedge Fund Holders: 3

Glenview Capital’s Stake: $487,711

Rapid Micro Biosystems, Inc. (NASDAQ:RPID) creates, sells, validates, and services innovative products for fast, accurate, and efficient detection of microbial contamination. There are several compelling factors that make this company a strong investment. The first is, as per the report for the third quarter of 2024, revenue was $7.6 million, representing a growth of 24% compared to the third quarter of the prior year. This indicates that the company is successfully executing its business strategies, attracting more customers or increasing sales. Secondly, the company has launched the Growth Direct Rapid Sterility application. This innovative solution delivers time-to-organism detection in as little as 12 hours and final time-to-result in as little as one to three days. This capability represents a significant improvement over widely used traditional test methods, which generally require a 14-day endpoint incubation, and provides compelling differentiation when compared to current rapid sterility products.

Overall RPID ranks 15th on our list of Larry Robbins’ long-term stock picks. While we acknowledge the potential of RPID as an investment, our conviction lies in the belief that some stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for a stock that is more promising than RPID but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap

Disclosure: None. This article is originally published at Insider Monkey.